HCV RNA viral load is independent from CD4 cell count and plasma HIV RNA viral load in immunocompetent HIV-HCV co-infected patients: A 3-years follow-up study

AIDS Research and Therapy

Volumn 11, Issue 1, 2014, Pages

  Basso, Monica ^a   Franzetti, Marzia ^a   Scaggiante, Renzo ^a   Sattin, Andrea ^a   Mengoli, Carlo ^a   Cruciani, Mario ^b   Fiscon, Marta ^a   Palù, Giorgio ^a   Parisi, Saverio G ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Center of Preventive Medicine and HIV Outpatient Clinic   (Italy)

Author keywords

Follow up; HCV genotype 1; HCV RNA; HIV RNA; Interleukin 28B CC allele

Indexed keywords

ABACAVIR; EMTRICITABINE; INTERLEUKIN 28B; LAMIVUDINE; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; MIDDLE AGED; MIXED INFECTION; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84904769086     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-11-21     Document Type: Article

References (28)

1. Andreoni M, Giacometti A, Maida I, Meraviglia P, Ripamonti D, Sarmati L. HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications. Eur Rev Med Pharmacol Sci 2012, 16:1473-1483.
2. Berenguer J, Rodri´guez E, Miralles P, Von Wichmann MA, Lo´pez-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Te´llez MJ, Quereda C, Jou A, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Esteban H, Bello´n JM, Gonza´lez-Garci´a J. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 2012, 55:728-736. 10.1093/cid/cis500, 22610932.
3. Davies A, Singh KP, Shubber Z, Ducros P, Mills EJ, Cooke G, Ford N. Treatment outcomes of treatment-nai¨ve Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts. PLoS One 2013, 8:e55373. 10.1371/journal.pone.0055373, 3564801, 23393570.
4. Basso M, Parisi SG, Mengoli C, Gentilini V, Menegotto N, Monticelli J, Nicole` S, Cruciani M, Palu` G. Sustained virological response and baseline predictors in HIV-HCV coinfected patients retreated with pegylated interferon and ribavirin after failing a previous interferon-based therapy: systematic review and meta-analysis. HIV Clin Trials 2013, 14:127-139. 10.1310/hct1404-127, 23924585.
5. Sulkowski MS. Current management of Hepatitis C Virus infection in patients With HIV co-infection. J Infect Dis 2013, 207:S26-S32. 10.1093/infdis/jis764, 3565592, 23390302.
6. Zeuzem S, Rodri´guez-Torres M, Rajender Reddy K, Marcellin P, Diago M, Craxi A, Pockros P, Rizzetto M, Bernstein D, Shiffman ML, Lin A, Tatsch F, Hadziyannis S. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin. J Viral Hepat 2012, 19:766-774. 10.1111/j.1365-2893.2012.01624.x, 23043383.
7. European Guidelines for treatment of HIV-infected adults in Europe. English online version 7.0 http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf.
8. Rallo´n NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, Shianna KV, Vispo E, Thompson A, McHutchison J, Soriano V. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010, 24:F23-F29. 10.1097/QAD.0b013e3283391d6d, 20389235.
9. Mira JA, Garci´a-Rey S, Rivero A, de los Santos-Gil I, Lo´pez-Corte´s LF, Giro´n-Gonza´lez JA, Te´llez F, Ma´rquez M, Merino D, Ri´os-Villegas MJ, Maci´as J, Rivero-Jua´rez A, Pineda JA. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Clin Infect Dis 2012, 55:1719-1726. 10.1093/cid/cis779, 22955435.
10. Rivero-Juarez A, Mira JA, Camacho A, Neukam K, Perez-Camacho I, Caruz A, Macias J, Torre-Cisneros J, Pineda JA, Rivero A. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV. Infection 2013, 41:21-26. 10.1007/s15010-012-0352-4, 23065463.
11. Kirk GD, Mehta SH, Astemborski J, Galai N, Washington J, Higgins Y, Balagopal A, Thomas DL. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013, 158:658-666. 10.7326/0003-4819-158-9-201305070-00604, 3708651, 23440167.
12. Collazos J, Carto´n JA, Asensi V. Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes. HIV Med 2011, 12:308-315. 10.1111/j.1468-1293.2010.00886.x, 20946441.
13. Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh JK, Mocroft A. Stability of hepatitis C virus (HCV) RNA levels among interferon-nai¨ve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med 2013, 14:370-378. 10.1111/hiv.12033, 23534815.
14. Rallo´n NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS 2011, 25:1025-1033. 10.1097/QAD.0b013e3283471cae, 21505315.
15. Labarga P, Soriano V, Caruz A, Poveda E, Di Lello FA, Hernandez-Quero J, Moreno S, Bernal E, Miro´ JM, Leal M, Gutierrez F, Portilla J, Pineda JA. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS 2011, 25:761-766. 10.1097/QAD.0b013e32834488e7, 21378537.
16. Barreiro P, Labarga P, Ferna´ndez-Montero JV, Poveda E, de Mendoza C, Sa´nchez C, Vispo E, Soriano V. Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. J Clin Virol 2013, 58:391-395. 10.1016/j.jcv.2013.06.031, 23910933.
17. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, McCallister S, Henshaw J, Girard PM, Adiwijaya B, Garg V, Rubin RA, Adda N, Soriano V. Combination therapy with telaprevir for chronic Hepatitis C Virus Genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013, 159:86-96.
18. Hua L, Andersen JW, Daar ES, Glesby MJ, Hollabaugh K, Tierney C. Hepatitis C virus/HIV coinfection and responses to initial antiretroviral treatment. AIDS 2013, 27:2725-2734. 10.1097/01.aids.0000432470.46379.dd, 23921611.
19. Parisi SG, Andreis S, Mengoli C, Scaggiante R, Ferretto R, Manfrin V, Cruciani M, Giobbia M, Boldrin C, Basso M, Andreoni M, Palu` G, Sarmati L. Baseline cellular HIV DNA load predicts HIV DNA decline and residual HIV plasma levels during effective antiretroviral therapy. J Clin Microbiol 2012, 50:58-63.
20. Laskus T, Kibler KV, Chmielewski M, Wilkinson J, Adair D, Horban A, Stan´czak G, Radkowski M. Effect of hepatitis C infection on HIV-induced apoptosis. PLoS One 2013, 8:e75921. 10.1371/journal.pone.0075921, 3788068, 24098405.
21. Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with HIV infection. Hepatology 2013, 58:249-257.
22. Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O, Mocroft A. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med 2013, 14:613-623.
23. Funk EK, Shaffer A, Shivakumar B, Sneller M, Polis MA, Masur H, Heytens L, Nelson A, Kwan R, Kottilil S, Kohli A. Short communication: Interferon/Ribavirin treatment for HCV Is associated with the development of Hypophosphatemia in HIV/Hepatitis C Virus-Coinfected patients. AIDS Res Hum Retroviruses 2013, 29:1190-1194.
24. Avidan NU, Goldstein D, Rozenberg L, McLaughlin M, Ferenci P, Masur H, Buti M, Fauci AS, Polis MA, Kottilil S. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr 2009, 52:452-458. 10.1097/QAI.0b013e3181be7249, 2783427, 19797971.
25. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Gu¨nthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012, 308:387-402.
26. Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, Klein, Machouf N, Montaner JS, Rourke S, Tsoukas C, Hogg B, Raboud J. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis 2012, 205:1230-1238. 10.1093/infdis/jis104, 3308904, 22438396.
27. Blanco F1, Barreiro P, Ryan P, Vispo E, Marti´n-Carbonero L, Tuma P, Labarga P, Medrano J, Gonza´lez-Lahoz J, Soriano V. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011, 18:11-16. 10.1111/j.1365-2893.2009.01261.x, 20088890.
28. Pineda JA, Aguilar-Guisado M, Rivero A, Giron-Gonzalez JA, Ruiz-Morales J, Merino D, Ri´os-Villegas MJ, Maci´as J, Lo´pez-Corte´s LF, Camacho A, Merchante N, Del Valle J. Natural history of compensated hepatitis C virus-related cirrhosis in human immunodeficiency virus-infected patients. Clin Infect Dis 2009, 49:1274-1282. 10.1086/605676, 19772387.